Exact Sciences Cologuard Plus

Exact Sciences has launched Cologuard Plus, an updated version of its noninvasive, stool-based colorectal cancer screening (CRC) test. The assay is FDA-approved for average-risk patients aged 45 and older and is covered by Medicare. Exact's data, from a 20,000+ patient study called BLUE-C, indicate that Cologuard Plus detects 95 percent of colorectal cancers at 94 percent specificity in the US screening population. This translates to up to a 40 percent reduction in unnecessary colonoscopies compared to the original Cologuard assay. As Exact Sciences works to expand patient access to the new Cologuard Plus test, its original Cologuard test will remain available.